Tech at Polsky
Inventor(s):
Universal, personalized T-cell cancer treatment
Selection of optimal TCRs in the context of both MHC I & II
Enhanced safety and minimized unpredictable cross-reactivity are eliminated which may be encountered when using TCRs from other sources
Adoptive T cell therapies for cancer
Cancer vaccine
January 31, 2022
Proof of concept
Patent Pending
Licensing,Co-development
Michael Bishop
Published 1/31/2022
Reference ID 21-T-088
Have Questions?
Contact Michael Hinton, Manager, Technology Marketing, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.
This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.